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Abstract
Background: miRNAs have been implicated in the regulation of key metabolic, inflammatory, and
malignant pathways; hence, they might be considered both predictors and players of cancer development.
Methods: Using a case–control study design nested in the ORDET prospective cohort study, we addressed
the possibility that specificmRNAs can serve as early predictors of breast cancer incidence in postmenopausal
women. We compared leukocyte miRNA profiles of 133 incident postmenopausal breast cancer cases and
profiles of 133 women who remained healthy over a follow-up period of 20 years.
Results: The analysis identified 20 differentially expressed miRNAs, 15 of which were downregulated.
Of the 20 miRNAs, miR145-5p and miR145-3p, each derived from another arm of the respective pre-miRNA,
were consistently and significantly downregulated in all the databases thatwe surveyed. For example, analysis
ofmore than 1,500 patients (theUKMetabric cohort) indicated that high abundance ofmiR145-3p andmiR145-
5pwas associatedwith longer, and formiR145-3p also statistically significant, survival. The experimental data
attributed different roles to the identifiedmiRNAs: Although the 5p isoformwas associatedwith invasion and
metastasis, the other isoform seems related to cell proliferation.
Conclusions:These observations and theprospective designof our study lend support to thehypothesis that
downregulation of specific miRNAs constitutes an early event in cancer development. This finding might be
used for breast cancer prevention.
Impact: The identification of the miRNAs as long-term biomarkers of breast cancer may have an impact on
breast cancer prevention and early detection. Cancer Epidemiol Biomarkers Prev; 23(11); 2471–81. 2014 AACR.
Introduction
The identification of molecular biomarkers associated
with cancer initiation and progression represents a fun-
damental step for the risk assessment and development of
new prevention strategies. A recently identified class of
noncoding small RNAs, miRNA, may provide new
insights into cancer prevention and early detection meth-
odology. MiRNAs are small, stable noncoding RNAs
whose function is to bind the messenger RNAs (mRNA)
of expressed genes and target them for degradation or
inhibition of translation, resulting in reduced expressed
protein levels (1). It is estimated thatmiRNAsmayactually
regulate up to two thirds of the human genome (2).
MiRNAs have been shown to be directly involved inmany
human cancers, including breast, lung, brain, liver, colon,
prostate, ovarian cancers, and leukemia (3). SomemiRNAs
function as tumor suppressors by negatively inhibiting
oncogenes that control cell differentiation and apoptosis,
whereas others act as oncogenes (oncomirs; refs. 4, 5).
There is agrowingconsensus thatmiRNAdownregulation
has a profound impact on the genesis of tumors (6–8).
There is evidence that an extensive downregulation of
miRNAs is one of the first biologic response of the
deregulation in a signaling cascade downstream of
specific growth factor receptors implicated in human
cancers, including breast cancer. For example, EGF
signaling rapidly and simultaneously induces a massive
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downregulation of multiple miRNAs, reflecting coordi-
nated regulation at the level of miRNA synthesis, pro-
cessing, or degradation (9).
In the present study, we aimed to test the hypothesis
that miRNAs (as a single entity or as a signature) may
represent early indicators of future breast cancer inci-
dence. Previous evidence indicated that miRNAs are
deregulated, and, in particular, mainly downregulated
in response to environmental/metabolic risk factors for
cancer (10–12). To test the working hypothesis, we com-
pared leukocyte miRNA profiles of healthy women who
subsequently became affected with breast cancer with
womenwho remainedhealthy. Thiswas performedusing
a case–control study design nested in the ORDET
[hORmones and Diet in the ETiology of Breast Cancer)
prospective cohort study over a follow-up period of 20
years. The prospective study design also allowed corrob-
orating the evidence that the downregulation of miRNAs
represents one of the very early molecular alterations
during the development of the disease. Subsequently, we
evaluated whether miRNAs differently expressed in the
ORDET women candidate to become breast cancer cases
versus control subjects were also modulated in breast
cancer tissues and had prognostic value using the well-
characterized METABRIC cohort of 1,359 breast cancer
cases (13). As the final phase of the study, we investigated
the functional activity of the identified miRNAs in breast
cancer cell lines.
Materials and Methods
Study design and population
The study has been conducted in the context of the
ORDET prospective cohort study; the analysis included
133 incident postmenopausal breast cancer cases and 133
matched control subjects.
The ORDET cohort was established in northern Italy
between June 1987 and June 1992, in which 10,786 healthy
women ages 35 to 69 years were enrolled (14). They were
all residents of theVarese province, an area covered by the
population-based Lombardy Cancer Registry (15). They
had heard about the study through the media, at public
meetings, and volunteered to participate. At recruitment,
we measured anthropometric variables and collected
demographic information and blood samples. Because
the study‘s focus was on endogenous hormones in rela-
tion to breast cancer risk, we also applied stringent inclu-
sion criteria and highly standardized conditions on the
collection of biologic samples.
Information on cancer outcomes available from the
Lombardy Cancer Registry has been linked to the ORDET
cohort to identify incident breast cancer cases up to
December 31, 2006 (16).
Case subjects were women who developed breast can-
cer after their recruitment into the ORDET cohort and
before the end of the follow-up. We randomly chose one
control for each case, from appropriate risk sets consisting
of all cohort members who satisfied the matching criteria
andwere alive and free of cancer at the timeofdiagnosis of
the index case. Matching characteristics were age (3
years) at enrollment and date of recruitment (180 days).
We applied an incidence density sampling protocol for
control selection (17).
After exclusion of women with a history of cancer and
women who, immediately after baseline, were lost to
follow-up (observed time ¼ 0), 10,633 participants rem-
ained to form the base population of ORDET.
In the ORDET study, as well as in other cohort studies,
we found that risk factors differ either in their phenotypic
expression or in their distribution by menopausal status
(18). Thus, the present report focused on the postmeno-
pausal group of the cohort, defined as those cohort mem-
bers who had the last menstrual period at least 12 months
before their enrollment in the study. In summary, within
the postmenopausal members of the cohort and because
of the selection criteria, we identified and included in the
study 133 incident breast cancer cases and 133 matched
control subjects.
miRNA in leukocytes
We evaluated the miRNA expression profile of leuko-
cytes derived from buffy coats collected at recruitment.
Blood collection
Blood samples were drawn after overnight fasting
between 7:30 am and 9:00 am from each woman and
stored at 80C.
Samples from each case and related control were han-
dled identically and assayed together in the same labo-
ratory session. Laboratory personnel were blinded to
case–control status.
Laboratory methods
RNA extraction, labeling, and microarray hybridiza-
tion. Leucocytes were lysed in 1 mL of TRI Reagent, a
lysis reagent from Ambion, according to the manufac-
turer’s instructions. The concentration and purity of total
RNA were assessed using a NanoDrop 1000 Spectropho-
tometer (NanoDrop Technologies). Total RNA (100 ng)
was labeled, hybridized toHumanmicroRNAMicroarray
V2 (Agilent Technologies), and scanned with Agilent
DNA Microarray Scanner (P/N G2565BA) according to
the manufacturer’s instructions. Feature Extraction Soft-
ware (Version 10.5) was used for data extraction from raw
microarray image files using the microRNA_105_Dec08
FE protocol. This miRNA Agilent expression profile was
submitted to the Gene Expression Omnibus (GEO) with
the accession number GSE54470. Minimum Information
About a Microarray Gene Experiment (MIAME) guide-
lines were followed as instructions. Furthermore, repre-
sentative RNA preparations were evaluated for integrity
using the 2100 Bioanalyzer RNA 6000 Nano Kit (Agilent
Technologies; data not shown).
We also assessed the expression ofmiR223 in randomly
selected samples by Northern blot analysis (data not
shown). miR223 is highly specific for hematopoietic cells
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and constitutes a regulator of myelopoiesis (19). The blot
was hybridized with a [32P]gATP-radiolabeled LNA oli-
gonucleotide complementary to miR223 sequence. The
specificity and strength of hybridization of ORDET RNA
samples was as good as that of human promyelocytic
HL60 cells treated with retinoic acid (106 mol/L), a
known inducer of miR223.
Microarray data analysis
Data were verified and extracted by the Agilent
Extraction 10.7.3.1 software and analyzed using an in-
house built routines by Matlab (The MathWorks Inc.).
Background-subtracted signal of 851 human miRNA
assays was used in the study. All arrays were quantile
normalized, assuming that all samples were measured
and analyzed under the same condition, enforcing all
the arrays to assume the same mean distribution. The
Pearson coefficient was calculated to assess the corre-
lation between technical replicates of some randomly
chosen samples.
We fitted a linear model to the expression values for
each miRNA, to assess the significance of differential
expression between case and control. In addition,weused
empirical Bayes methods implemented in the LIMMA
package to construct moderated t statistics and incorpo-
rated the statistical tools to adjust for the multiplicity of
the tests. The Benjamini andHochbergmethod (1995)was
used to control for false discovery.
We considered the linear model including the matched
case–control study design, the case–control status, and
the error term.
Statistical methods
Data preprocessing anddifferential expression analysis
were done using the Bioconductor AgiMicroRna package
(20). The Total Gene Signal (TGS) provided by the Agilent
Feature Extraction image analysis software was used as
the quantitativemeasure ofmiRNA expression.We set all
negative TGS values to 0.5 before log transformation,
so that the log ratios are shrunk toward zero at lower
intensities. The miRNA expression data (i.e., TGS) were
quantile normalized before determining differential
expression. The data were analyzed using the R software
package. For differential expression analysis, the AgiMi-
croRna package incorporates the linear model with
matched pair features from the Bioconductor LIMMA
package (21). The LIMMA approach fits a linear model
to the expression value for each miRNA to assess the
significance of differential expression between different
experimental conditions. In addition, the method uses
empirical Bayes methods (22) to construct moderated t
statistics and incorporates statistical tools to adjust for
multiple testing. The Benjamini and Hochberg method
(23)wasused to control for false discovery rate (FDR), and
we ranked themiRNAs according to FDR.We considered
the top-ranked 20 miRNAs and investigated the upregu-
lated and downregulated miRNAs identified from post-
menopausal samples. We computed agglomerative hier-
archical clustering of the dataset. At first, each object is
assigned to its own cluster and then the algorithm pro-
ceeds iteratively. At each stage, the two most similar
clusters are combined to form a larger cluster, continuing
until there is just a single cluster. At each stage, distances
between clusters are computed by the Lance–Williams
dissimilarity update formula. Details about the cluster-
ing algorithm are given in the book by Kaufman and
Rousseeuw (24). This clustering method partitions the
dataset into clusters, in which similar miRNA expres-
sion patterns are assigned to the same cluster.
We identified predictive pathways using pathway
analysis. Pathway analysis was performed by DIANA
miRPath v2.0. The software calculated the union of
targeted genes by the selected miRNAs (UNION_SET,
all genes targeted by at least one selected miRNA). The
Table 1. Descriptive characteristics of the 133 postmenopausal women candidate to become breast
cancer and 133 control women: baseline values
Cases Controls
Median
difference
(IC 95%)
t Student
P value
Age, y; median (SD) 57 (5.95) 56 (5.89) 0.5:2.5 0.85
Age at menarche, y; median (interquartile range) 13 (12–14) 13 (12–14) 0.36:0.36 0.93
IGF1; median (interquartile range) 115 (95.5–155) 111 (92.2–137.5) 6.2:14.2 0.16
TTS; median (interquartile range) 0.28 (0.21–0.36) 0.26 (0.2–0.32) 0.02:0.06 0.21
BMI, kg/m2; median (interquartile range) 25.6 (23.3–28.3) 25.7 (23.6–28.4) 1.13:0.78 0.42
Fasting glucose; median (interquartile range) 84 (78–91) 85 (78–90) 7.8:5.8 0.24
Alcohol intake, g/d; median (interquartile range) 4.8 (0–24) 3.4 (0–18) 2.3:5.1 0.75
Age at ﬁrst birth; median (SD) 26 (4.6) 25 (3.6) 0.09:2.1 0.09
Full-term pregnancies; median (SD) 2 (1) 2 (1) 0.28:0.28 0.92
Smoking; % of smoker/ex smoker/not smoker 19/12/69 16/12/72 — 0.7a
Abbreviations: IGFI, insulin growth factor 1; TTS, total testosterone.
ax2 P value.
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UNION_SET set was used for the statistical analysis.
This enrichment analysis identified the pathways
significantly enriched with genes belonging to the
UNION_SET (25).
To assess the miRNAs’ prognostic value, we con-
ducted a survival analysis in the Metabric cohort of
breast cancer cases. This analysis was not possible on
the ORDET cohort study database for the limited sam-
ple size of the breast cancer–specific mortality events.
The Metabric cohort is a very well-characterized breast
cancer database provided with matching detailed clin-
ical annotation, long-term follow-up, and genomic and
miRNA expression data (13). The database includes
1,302 breast tumors, which included a subgroup of 81
breast cancer cases, where each case was provided with
samples derived from both the tumoral lesion and the
related normal breast tissue. As an initial step of the
survival analysis, we tested the consistency of the dis-
regulation (down- versus upregulation) between the
observed 20 top-ranked miRNAs in the ORDET cohort
and in the tumor tissue versus the normal tissue in the
subgroup of 81 breast cancer cases described in the
Metabric study. For instance, the downregulated miR-
NAs in ORDET breast cancer cases versus control sub-
jects were expected to have lower expression levels in
breast tumors versus normal tissue. In the subsequent
survival analysis, higher expression levels of these
miRNAs were expected to be associated with better
survival. We expected the opposite effect for the ORDET
upregulated miRNAs. For testing the prognostic value,
for each miRNA, we computed the P value for its
differential expression between tumor tissue and nor-
mal tissue (in the subgroup of patients provided with
samples of both tumor and normal tissue). Subsequent-
ly, for each miRNA, we performed survival analysis and
generated Kaplan–Meier plots.
Methods of the experimental study
Cell cultures and transfection. Human breast
cancer cell lines MDA-MB-231 and MDA-MB-468 were
obtained from the American Type Culture Collection
(ATCC; www.atcc.org). ATCC uses morphology, kar-
yotyping, and PCR-based approaches to confirm the
identity of human cell lines and to rule out both intra-
and interspecies contamination (www.atcc.org). After
purchasing, (5 months ago) the cells were routinely
tested with PCR approaches. For mature miR145-5p
and miR145-3p expression, we used Pre-microRNA
Precursor-Negative Control (Ambion), Pre–miR145-5p
(Ambion), and Pre–miR145-3p (Ambion) at a final con-
centration of 5 nmol/L.
The expression levels of miR145-3p and miR145-5p
were evaluated by PCR (Supplementary Fig. S1)
Cell proliferation assay. MDA-MB-231 cells were
seeded into 6-well dishes and transfected in triplicates as
indicated. Cells (6  104) were seeded for this assay.
Cells were collected and manually counted at 0, 24, 48,
72 hours after transfection.
Transwell migration assay. Migration assay was
performed using a 24-well Boyden chamber with a
noncoated 8-mm pore size filter in the insert chamber
(BD Falcon). Cells (mimic 145-5p and control-trans-
fected MDA-MB-231 and MDA-MB-468; 5  104) were
suspended in 0.5 mL DMEM without FBS and seeded
into the insert chamber. Cells were allowed to migrate
for 48 hours into the bottom chamber containing 0.7 mL
of DMEM containing 5% FBS in a humidified incubator
at 37C in 5% CO2. Migrated cells that had attached to
the outside of the filter were visualized by staining with
DAPI and counted.
Clonogenic assays. MDA-MB-231 cellswere grown to
70% confluence and transfected as indicated. Colony
staining and counting were performed as described by
Biagioni and colleagues (7).
Table 2. List of the top 20-ranked miRNAs
according to FDR values for miRNAs
differentially expressed between women
candidate to become breast cancer and healthy
controls within the ORDET cohort
miRNA Log FCa P valuesb FDRc
Downregulated miRNAs
hsa-miR125a-5p 0.634 0.0021 0.400
hsa-miR141 0.158 0.0023 0.400
hsa-miR582-5p 0.496 0.0028 0.400
hsa-miR138 0.199 0.0034 0.400
hsa-miR199a-5p 0.581 0.0039 0.400
hsa-miR181c* 0.321 0.0041 0.400
hsa-miR28-3p 0.631 0.0042 0.400
hsa-miR224 0.629 0.0047 0.400
hsa-miR145-3p 0.261 0.0053 0.408
hsa-miR223 0.484 0.0079 0.503
hsa-miR145-5p 0.506 0.0083 0.503
hsa-miR539 0.364 0.0098 0.504
hsa-miR99b 0.483 0.0112 0.504
hsa-miR199b-5p 0.314 0.0117 0.504
hsa-miR920 0.147 0.0118 0.504
Upregulated miRNAs
hsa-miR892b 0.460 0.0001 0.102
hsa-miR1288 0.304 0.0045 0.400
hsa-miR520a-3p 0.402 0.0061 0.430
hsa-miR542-5p 0.381 0.0102 0.504
hsa-miR122* 0.393 0.0118 0.504
NOTE: Downregulated and upregulated miRNAs in candi-
dates to become breast cancer cases versus controls.
aThe Log FC column gives log2 fold change between cases'
and controls' expression.
bP values for moderated t statistics.
cFDR gives the P value adjusted with the Benjamini and
Hochberg method to control the FDR.
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Results
Most of the baseline characteristics did not differ
between the 133 breast cancer cases and 133 controls
(Table 1), in particular for age, reproductive, hormonal,
and life-style risk factors that could have represented
confounders of the studied association.
When we conducted class comparisons to identify
differentially expressed miRNAs, we first performed a
moderated t test (22) for each miRNA on all 266 postmen-
opausal women.Most of the difference inmiRNA expres-
sion between cases and controls was toward the down-
regulation in women who were later affected with breast
cancer.
Table 2 reports all the top-ranked 20 miRNAs (ranked
according to FDR values). Of these 20 miRNAs, 15 (75%)
were downregulated. Among the upregulated miRNAs,
miRNA892b was characterized by the lowest FDR (close
to 10%), resulting in the most statistically significant
differentially expressed miRNA.
An examination of miRNA expression revealed that
the 20 top-ranked miRNAs were grouped in three differ-
ent clusters. Figure 1 shows the heatmap of the distinct
miRNA profiles following an unsupervised hierarchical
clustering analysis. None of the reported 20 top-ranked
miRNAs correlate to age (in either cases or controls),
bodymass index (BMI), serum fasting glucose, and serum
Figure1. Heatmapof top-ranked20miRNAs frompostmenopausal samples. Theheatmapprovided insight into thedata structure for eachmiRNAandsample.
We used red and green colors for deﬁning low and high expression values. Blue, cases; yellow, controls. The clustering methods partitioned the dataset into
three clusters, identiﬁed on the left of the ﬁgure. Each miRNA is listed on the right.
miRNAs as Long-term Predictors of Breast Cancer Occurrence
www.aacrjournals.org Cancer Epidemiol Biomarkers Prev; 23(11) November 2014 2475
on July 27, 2019. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst July 29, 2014; DOI: 10.1158/1055-9965.EPI-14-0398 
fasting insulin. When we looked at the hormone receptor
status of the ORDET incident breast cancer cases (e.g.,
estrogen andprogesterone receptor status in breast cancer
cases), in the subgroup of progesterone receptor–positive
cases,we found that lowexpression levels ofmiR99bwere
statistically associated with a higher probability to devel-
op progesterone receptor–positive breast cancer.
In Table 3, we describe the most significant cancer
predicted pathways targeted by the three clusters. It is
worth noting that most of the pathways identified by the
clusters of differentially expressed miRNAs were related
to both breast cancer and more general cancer develop-
ment (e.g., ErbB, mTOR, TGFb, Hedgehog, and Wnt
pathways; refs. 26–30). We then observed that the
three miRNA clusters targeted pathways also related to
metabolic and endocrine systems, such as cholesterol
synthesis, steroid biosynthesis, and the insulin pathway
recognized in the ORDET cohort, as well as in other
studies as pathways involved in breast cancer develop-
ment (27, 31, 32). Finally, the mitogen-activated protein
kinase (MAPK) pathwaywas targeted at a very high level
of statistical significance by all the three clusters.
We also noticed that among the top 20 differentially
regulated miRNAs, a pair of downregulated miRNAs
share the same precursor: the miR145-3p and miR145-
5p located on chromosome 5.
To further investigate the consistency of the observed
downregulation of miR145-3p and miR145-5p in breast
cancer, we analyzed three different publicly available
databases of miRNA expression in breast cancer
[GSE28884 (33) and GSE19536 (34) and The Cancer
Genome Atlas Network (35)] and Biagioni and collea-
gues article database (7). As shown in Tables 4 and 5,
miR145-3p and miR145-5p were consistently downre-
gulated across all databases in tumor tissue versus
peritumoral or normal tissues.
In Table 6, we also included, as the fifth database, the
comparison between the tumor tissue and the normal
tissue observed in the Metabric cohort study: Again,
both miRNAs were downregulated in the tumor tissue
versus normal tissue at a very high level of statistical
significance. We conducted the same analysis for all the
remaining 18 miRNAs; however, we did not notice a
similar level of consistency for any of them (Table 6 and
Supplementary Tables S1–S18). For instance, the down-
regulated miRNA-199a-5p allocated in the first cluster
was equally downregulated in both tumor tissue and
normal tissue in the Metabric study (13) and upregu-
lated in the Biagioni and colleagues study (ref. 7; Sup-
plementary Table S1).
To evaluate whether miR145-3p andmiR145-5p played
a role in the progression of breast cancer, we analyzed the
disease-specific survival rate as a function of their lowand
high expression. In the Metabric breast cancer cohort, we
saw that the high expression of both miR145-3p and
miR145-5p was associated with longer survival: For
miR145-3p, the differencewith its low expression reached
statistical significance (Fig. 2).
As the final step of our study, we investigated the
functional activity of miR145-3p and miR145-5p in
MDA-MB-231 and MDA-MB-468 breast cancer cell lines.
We used these breast cancer cell lines, which are both
Table 3. Cancer predicted pathways targeted by the three clusters identiﬁed by the cluster analysis
miRNA cluster Most signiﬁcant predicted pathways
Cluster 1 Wnt signaling pathway
miR145-5p miR199a-5p miR542-5p miR892b miR1288 Steroid biosynthesis
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis
Hedgehog signaling pathway
Adherens junction
Transcriptional misregulation in cancer
Pathways in cancer
TGFb signaling pathway
MAPK signaling pathway
Cell cycle
Cluster 2 MAPK signaling pathway
miR28-3p miR122 miR138 miR141 miR145-3p miR181c
miR520-3p miR539 miR920
ErbB signaling pathway
mTOR signaling pathway
Insulin signaling pathway
PI3K-Akt signaling pathway
Transcriptional misregulation in cancer
Chemokine signaling pathway
Cluster 3 MAPK signaling pathway
miR99b miR582-5p miR199b-5p Transcriptional misregulation in cancer
Pathways in cancer
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representative of a basal-like phenotype, because they
were previously used by Sachdeva and Mo, to demon-
strate the involvement of miR145-5p in breast cancer
invasion and metastatization (36). Because this breast
cancer histotype is known to be the most aggressive one,
it is also the best model to perform a migration assay. As
reported in Fig. 3A–E, we observed that the two miRNAs
had different and complementary activities in controlling
breast cancer cells. Ectopic expression ofmiR145-5p inhib-
ited cell migration but did not affect proliferation of the
analyzed breast cancer cell lines (Fig. 3B). On the contrary,
overexpression of miR145-3p impinged on cell prolifera-
tion and colony formation, but had no effect on cell
migration (Fig. 3C and D); we did not observe any effect
of miR145-3p on the migration of breast cancer cells
(Fig. 3E).
Discussion
In this study, we provide evidence that miRNAs
might serve as early indicators of breast cancer occur-
rence. We observed that in leukocytes collected from
healthy women who later became affected with breast
cancer, differences were found in miRNA expression
profiles, in comparison with leukocytes of women
who did not develop the disease during the same
follow-up period. The observation that among the
microRNAs listed in the top 20 most differentially
expressed microRNAs, 15 were down-regulated, sup-
ports our working hypothesis that downregulation of
regulatory miRNAs might herald breast cancer initia-
tion. This concept has also been experimentally valida-
ted by the progressive downregulation of miRNAs
observed when passing from healthy breast tissue to
breast cancer with high cell-proliferation rates (37).
The high blood stability of miRNAs, their resistance to
RNA degradation, and their reproducible detectionmake
miRNAs suitable biomarker candidates (38). A number of
lifestyle factors and conditions, often related to inflam-
mation status, have been reflected into specific deregula-
tion ofmiRNA in peripheral leukocytes (39). Lifestyle and
dietary factors are both related to inflammation status and
Table 5. miR145-5p modulation in breast cancer cases and in a variety of breast cancer tissues and
peritumoral tissues by different databases
miR145-5p ORDET Biagioni et al. (7) CGAN Farazi et al. (33) Enerly et al. (34)
Tumor 133 (cases) 63 694 168 101
Peritumor — 59 83 — —
Normal 133 (controls) — — 11 —
Platform Agilent Agilent Illumina Solexa Agilent
Subsets Case vs. control T vs. PT Lum. B vs. Basal DCIS vs. normal; Basal vs, Lum A;
IDC HER2þ ER vs. normal mut p53 vs. wt p53;
ER-p53 mut vs. ER-p53 wt
proliferative samples
Modulation Down Down Down Down Down
Abbreviations: basal, basal breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma; lum,
luminal breast cancer; mut p53, mutated p53; PT, peritumoral tissue; T, tumor tissue; wt, wild-type.
Table 4. miR145-3p modulation in breast cancer cases and in a variety of breast cancer tissues and
peritumoral tissues by different databases
miR145-3p ORDET Biagioni et al. (7) CGAN Farazi et al. (33) Enerly et al. (34)
Tumor 133 (cases) 63 694 168 101
Peritumor — 59 83 — —
Normal 133 (controls) — — 11 —
Platform Agilent Agilent Illumina Solexa Agilent
Subsets case vs. control T vs. PT Lum A-B vs. basal — Basal vs. Lum A
mut p53 vs. wt p53
ER-p53 mut vs. ER-p53 wt
proliferative samples
Modulation Down Down Down — Down
Abbreviations: basal, basal breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma; lum,
luminal breast cancer; mut p53, mutated p53; PT, peritumoral tissue; T, tumor tissue; wt, wild-type.
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breast cancer risk. Macronutrient intake, characteristic of
the Western diet, and obesity may activate inflammatory
signaling pathways (40). Elevated levels of the proinflam-
matory cytokines promote angiogenesis, tumor progres-
sion, and metastasis (41).
The role of miRNAs isolated from leukocytes as bio-
markers of cancer occurrence has been underlined in this
studyby thepredictedpathwayanalysis conductedon the
basis of the three miRNA clusters. All clusters seem to
target, with the highest level of statistical significance,
pathways related to both breast and other cancer devel-
opment. At the same time, the clusters targeted genes
involved in metabolic and hormone risk factors for breast
cancer.
When considering miR145-3p and miR145-5p down-
regulation, we found that it was consistent across
five unrelated databases, with their high expression
associated with better survival. This association was
statistically significant for miR145-3p. This was further
corroborated by our findings that miR145-3p apparently
controls cell proliferation, whereas miR145-5p’s activity
seems to modulate cell migration and invasion. Thus,
we propose that biologic functions of these twomiRNAs
might differ according to the different phases of cancer
development. The twomiRNAs derive from each arm of
their pre-miR hairpin. In a previous publication of our
group, Biagioni and colleagues (7) observed a similar
opposite and complementary behavior of two miRNAs
that, similar to miR145-3p and miR145-5p, shared the
same precursor: miR10b-5p and miR10b-3p. The over-
expression of miR10b-5p was associated with tumor
invasion and metastasis (42), whereas the overexpres-
sion of miR10b-3p was related to cell-cycle progression
and proliferation (7). Following this model, we may
consider miR145-3p downregulation as a very early
signal of breast cancer development for its specific
control of the first step of carcinogenesis: cell prolifer-
ation. miR145-5p has been shown to act as a tumor
suppressor in different tumor types (36). Its downregu-
lation was associated with neoplastic cell growth, inva-
sion, and metastasis and is paired with increased
expression of different oncogenic mRNA targets expres-
sion, such as EGFR, MYC, MUC1, OCT4, and RTKN
(8, 36, 43).
There is very scarce evidence on the involvement
of miR145-3p in cancer progression. Indeed, Camps
and colleagues (44) observed downregulation of
miR145-3p expression in MCF-7 cells exposed to
hypoxia.
The evidence showing that only two miRNAs out of 20
were corroborated in all different databaseswas expected.
Differences in phase of the natural history of the disease at
sample collection (ORDETwas based on samples derived
from women still healthy, whereas all the other samples
were derived from breast cancer lesions) and differences
in study design reflected in differences in study popula-
tions by age and/or menopausal status may explain the
results. In particular, a comparison of miRNA profiling
between leukocyte samples (ORDET) and tissue samples
(Metabric and the other database) represents a limitation
for our direct study inference because miRNA profiling
was performed in different tissues. However, we hypoth-
esized that leukocyte miRNA profile (ORDET samples)
did reflect, in still healthy women, exposure to nutritional
and metabolic determinants of breast cancer. Then, dif-
ferences in miRNA profiling between women who later
developed breast cancer and women who remained
healthy had potential etiologic meaning. Subsequently,
in the Metabric study, as well as in other databases, we
investigated whether tissue from breast cancer cases, as a
later event, reflected similar miRNA profiling, effect of
exposure to risk factors, we observed in leukocytes col-
lected from those ORDET women candidate to develop
breast cancer.
The prospective nature of the observation that specific
miRNAs were deregulated in leukocytes collected from
healthy women to develop breast cancer 20 years before
disease onset makes our study unique when compared
with previous studies. The prospective design of our
study assigns to both miR145-3p and miR145-5p a role
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Figure 2. Breast cancer disease-speciﬁc survival bymiRNA expression. Kaplan–Meier analysis for the association between (A) miR145-3p and (B) miR145-5p
expression levels with survival of patients with breast cancer (based on the METABRIC dataset). For each miRNA, we compared the third of patients
with the highest expression levels of the correspondedmiRNA (red) to the third of patients with the lowest expression (blue). ThemiRNA name andP value are
indicated in the title.
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as long-term breast cancer predictors and it also opens a
new avenue for prevention.
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